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The mechanisms involved in angiotensin II type 1 re-
ceptor (AT1-R) trafficking and membrane localization
are largely unknown. In this study, we examined the
role of caveolin in these processes. Electron microscopy
of plasma membrane sheets shows that the AT1-R is not
concentrated in caveolae but is clustered in cholesterol-
independent microdomains; upon activation, it partially
redistributes to lipid rafts. Despite the lack of AT1-R in
caveolae, AT1-Rcaveolin complexes are readily detecta-
ble in cells co-expressing both proteins. This interaction
requires an intact caveolin scaffolding domain because
mutant caveolins that lack a functional caveolin scaf-
folding domain do not interact with AT1-R. Expression
of an N-terminally truncated caveolin-3, CavDGV, that
localizes to lipid bodies, or a point mutant, Cav3-P104L,
that accumulates in the Golgi mislocalizes AT1-R to lipid
bodies and Golgi, respectively. Mislocalization results in
aberrant maturation and surface expression of AT1-R,
effects that are not reversed by supplementing cells
with cholesterol. Similarly mutation of aromatic resi-
dues in the caveolin-binding site abrogates AT1-R cell
surface expression. In cells lacking caveolin-1 or caveo-
lin-3, AT1-R does not traffic to the cell surface unless
caveolin is ectopically expressed. This observation is
recapitulated in caveolin-1 null mice that have a 55%
reduction in renal AT1-R levels compared with controls.
Taken together our results indicate that a direct inter-
action with caveolin is required to traffic the AT1-R
through the exocytic pathway, but this does not result in
AT1-R sequestration in caveolae. Caveolin therefore acts
as a molecular chaperone rather than a plasma mem-
brane scaffold for AT1-R.
Lipid-based sorting mechanisms play an important role in
the organization of the plasma membrane into microdomains
(1–3). The biophysical properties of sphingolipids and choles-
terol drive the spontaneous formation of lateral assemblies of
liquid-ordered lipid rafts in a sea of liquid-disordered phospho-
lipids. The biological importance of lipid rafts follows from the
lateral segregation that they impose on membrane proteins.
The differential distribution of plasma membrane proteins
across raft and nonraft membranes in turn results in the con-
centration of specific groups of signaling proteins and lipids
within discrete areas of the cell membrane (3–6). This in-
creases the efficiency and specificity of signaling events by
allowing more efficient interactions between proteins and by
preventing cross-talk between different pathways.
Caveolae are an abundant surface feature of many mamma-
lian cells and represent a specific subtype of lipid raft. Func-
tionally, caveolae have been implicated in endocytosis (7), po-
tocytosis (8), transcytosis (9), apical transport (10), and
cholesterol balance (11). Caveolae are identified by their char-
acteristic morphology (flask-shaped, 55–65-nm diameter pits)
and the presence of integral membrane proteins, termed caveo-
lins, of which three mammalian isoforms have been character-
ized (caveolin-1, -2, and -3) (12–14). Caveolins show the char-
acteristic biochemical features of raft-associated proteins,
being associated with low density detergent-insoluble com-
plexes that are sensitive to cholesterol depletion (15, 16).
Caveolins are crucial structural components of caveolae. Ex-
pression of caveolin-1 in cells lacking caveolae causes de novo
formation of caveolae, whereas ablation of caveolin expression
causes a loss of caveolae in cultured cells and in vivo (17, 18).
The ability of caveolins to bind cholesterol and to form high
molecular weight oligomeric complexes is presumably impor-
tant in caveolae formation. Caveolin-1 and caveolin-2 form
hetero-oligomeric complexes and are most prevalent in endo-
thelial cells, smooth muscle cells, skeletal myoblasts, fibro-
blasts, and adipocytes (19), whereas caveolin-3 (Cav3)1 is ex-
clusively present in muscle cells including cardiac myocytes
and cells of the arterial vasculature (20).
As well as this structural role, caveolins have also been
directly implicated in interactions with signaling proteins. A
juxtamembrane region of caveolin, the caveolin scaffolding do-
main (CSD) binds in vitro to a consensus sequence of
XXXXXXX (where  is an aromatic amino acid and X is
any amino acid) that is found in a large number of signaling
proteins including G-proteins, conserved kinase domain IX,
and elsewhere in many nonkinases (21–23). Caveolin has
therefore been postulated to act as a protein scaffold for sig-* This work is supported by grants from the National Health and
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naling proteins and to sequester them in caveolae (23), al-
though such interactions cannot be important in tethering pro-
teins to noncaveolar lipid rafts.
The association of lipid-modified peripheral membrane pro-
teins with lipid rafts is determined in part by the biophysical
properties of the hydrophobic modification of the membrane
anchor. Partitioning into rafts is favored if the lipid anchor is
saturated, although in the case of prenylated and palmitoy-
lated H-Ras activation state and additional protein sequences
adjacent to the membrane anchor also influence raft associa-
tion (24). Less clear is how transmembrane proteins are tar-
geted to lipid rafts. A well studied example is the epidermal
growth factor receptor (EGF-R) that is extensively localized to
lipid rafts in quiescent cells (25). The receptor is not lipid-
modified, but recent work has shown that a 60-amino acid
region in the extracellular domain of the EGF receptor, contig-
uous with the transmembrane domain of the receptor, is suffi-
cient for lipid raft targeting (26). The angiotensin II (AngII)
type 1 receptor (AT1-R) is a nonpalmitoylated G-protein-cou-
pled receptor (GPCR) that in smooth muscle cells co-immuno-
precipitates with caveolin and when activated co-fractionates
with caveolin on sucrose gradients (27). The interaction be-
tween the AT1-R and caveolin may be mediated by a CSD-
binding sequence at the C terminus of the receptor (28). Similar
to caveolin, the AT1-R is found in many cell types including
smooth and cardiac muscle cells as well as endothelial and
epithelial cells (29). These observations have led to the hypoth-
esis that an AT1-Rcaveolin complex in caveolae may coordinate
AngII-induced signaling (27). However, in contrast to the
EGF-R that exits lipid rafts following ligand binding and acti-
vation (4), activated AT1-R moves into lipid rafts and/or caveo-
lae where it transactivates the EGF-R (31).
Recent electron microscopic studies have shown that the
EGF-R is not concentrated in caveolae (32), although similar
data on the AT1-R are lacking. In this study we used quanti-
tative electron microscopy to examine the surface distribution
of ectopically expressed AT1-R. In addition, we show a physical
interaction between the AT1-R and caveolin and use dominant-
interfering mutants of caveolin to investigate interactions be-
tween caveolin and the AT1-R both at the plasma membrane
and during trafficking through the exocytic pathway. We show
that inactive AT1-R is found in cyclodextrin-resistant and -sen-
sitive clusters but is not enriched in surface caveolae; treat-
ment with AngII results in the partial relocalization of acti-
vated AT1-R into noncaveolar lipid rafts. Nevertheless,
expression of mislocalized caveolin mutants, the absence of
caveolin, or disrupting the formation of a caveolinAT1-R com-
plex has a profound effect on the trafficking of AT1-R from the
ER to the plasma membrane. In addition, mouse studies indi-
cate that caveolin is required for normal renal AT1-R expres-
sion. Together these data suggest an important chaperone role
for caveolin in trafficking a transmembrane receptor to the
cell surface.
EXPERIMENTAL PROCEDURES
Plasmids—N-terminally HA-tagged AT1-R (HA-AT1-R) and C-termi-
nally GFP-tagged AT1-R (GFP-HA-AT1-R) have been described (33, 34).
A truncated version of the HA-AT1-R was generated by deleting 34
amino acids C-terminal to Lys325 (AT1-R,TK325) (35). AT1-R mutants
with substitutions of key hydrophobic (Tyr302, Phe304, Phe309, and
Tyr312; YFFY/A) and positively charged residues (Lys307, Lys308, Lys310,
and Lys311; KKKK/Q) within the proximal C terminus (helix VIII) were
generated using PCR-based site-directed mutagenesis (ExSite). The
template for YFFY/A was a HA-tagged version of a previously reported
AT1-R mutant (Y302A) (35), whereas the template for KKKK/Q was
HA-AT1-R. The mutant receptors were sequenced to confirm the entire
coding region and the relevant nucleotide mutations. HA- and GFP-
tagged full-length Cav3 (151 residues), CavDGV (residues 54–151),
Cav3-P104L (Pro 3 Leu substitution at residue 104), HA-tagged Cav-
LLS (residues 75–151), and CavDGV-G55S (residues 54–154 with a
Gly3 Ser substitution at residue 55) are as described (36). For GFP-tH,
GFP is targeted to the plasma membrane by the minimal H-Ras anchor,
which has been described previously (37). GFP-Icmt was a kind gift of
Dr. Mark Philips (New York University). Caveolin-1-deficient mice
have been described previously (38).
Cell Culture and Transfection—Baby hamster kidney (BHK) and
Human embryonic kidney (HEK) cells were cultured at 37 °C in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented with 10%
bovine calf serum. The cells were plated at 60% confluency and
transfected using LipofectAMINE (Invitrogen) according to the man-
ufacturer’s instructions. After 5 h of incubation with transfection mix-
ture, the cells were washed with serum-free medium, and medium
containing 10% calf serum was added for overnight incubation. Where
indicated cholesterol depletion was performed using 1% cyclodextrin
(Sigma) in DMEM for 30 min following 20 h of serum starvation as
described (39). Cholesterol replenishment was carried out for 1 h using
a mix of 16 g/ml cholesterol in 0.4% cyclodextrin in DMEM as de-
scribed (39). Fischer rat thyroid (FRT) cells were cultured in DMEM
supplemented with 10% serum supreme at 37 °C. The cells were elec-
troporated with expression plasmids. After 24 h, the cells were pro-
cessed for confocal microscopy or biochemical analysis.
Cell Fractionation—Transfected BHK cells were washed with ice-
cold phosphate-buffered saline, scraped on ice into 0.3 ml of Buffer A (10
mM Tris-HCl, pH 7.5, 5 mM MgCl2, 1 mM EGTA, 1 mM dithiothreitol, 1
M NaVO4, 25 mM NaF, 10 g/ml leupeptin, and 10 g/ml aprotinin)
and homogenized through a 23-gauge needle. Post-nuclear superna-
tants obtained by low speed centrifugation were spun at 100,000  g at
4 °C for 30 min, and the soluble fraction (S100) and the sedimented
fraction (P100) were collected. The P100 fraction, which contains cellu-
lar membranes, was rinsed and resuspended in Buffer A.
Western Blotting—Protein content was measured by the Bradford
reaction. 20-g samples of the S100 and P100 fractions were separated
on 10, 12, or 15% SDS-polyacrylamide gels and transferred to polyvi-
nylidene difluoride membranes. Western blotting protein was performed
using anti-HA (Babco) or anti-GFP (Roche Applied Science) antibodies.
Western blots were developed using horseradish peroxidase-conjugated
secondary antibodies and ECL (SuperSignal; Pierce) and quantified by
phosphorimaging (Bio-Rad) as described previously (40).
Confocal Microscopy—Transfected BHK and FRT cells were washed
with phosphate-buffered saline, fixed with 4% paraformaldehyde for 30
min at room temperature, and permeabilized with 0.2% Triton X-100
for 10 min. After blocking in phosphate-buffered saline containing 3%
bovine serum albumin, BHK cells were incubated with anti-HA anti-
body in a humidified chamber for 1 h. FRT cells were incubated with an
anti-Cav3 antibody (Transduction Laboratories). The cells were then
washed in phosphate-buffered saline and Cy3-coupled anti-mouse sec-
ondary antisera used to visualize protein expression. The coverslips
were mounted in Mowiol for confocal microscopy (37).
Electron Microscopy and Statistics—Flat sheets of plasma membrane
prepared from transfected BHK cells were immunogold-labeled with
anti-GFP 5-nm gold and processed for image and statistical analysis
exactly as described (41, 42). Briefly, background was removed from
digitized negatives using Adobe Photoshop 5.0, and the gold particle
co-ordinates were determined using NIH Image 1.82. Subsequent Rip-
ley’s K-function analysis was performed using visual basic programs
written into Excel macros (41, 42). Positive deflections of the L(r)-r
curve outside the 99% confidence interval for complete spatial random-
ness (standardized to 1 on the figures) indicate significant clustering of
the gold pattern at the radius r (measured in nm) at which the deviation
occurs (a more detailed explanation of the statistical theory and inter-
pretation is given in Ref. 41). The gold patterns were further evaluated
using a mathematical model of plasma membrane microdomains essen-
tially as described previously (41). Gold particles were allocated to two
types of microdomain: lipid rafts with a mean radius of 20 nm or
nonrafts with a mean radius of 30 nm; in addition a fraction of particles
were allocated randomly over the study area. The two types of microdo-
main were randomly generated over the model study area and had no
fixed relationship to each other. All possible relative allocations of gold
particles to raft, nonraft, or the random fraction were evaluated at the
gold density achieved experimentally. Twenty Monte Carlo simulations
were run for each assignment of particles. The mean K-function was
calculated for each model pattern, and goodness-of-fit was evaluated by
calculation of the root mean square deviation from the observed data.
The model giving the lowest root mean square deviation was accepted
as the best fit.
Radioligand Binding—BHK cells grown in 6-well plates and HEK
cells grown in 12-well plates were transfected 24 and 48 h prior to
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radioreceptor assay, respectively. BHK cells were incubated in a bind-
ing buffer (50 mM Tris-HCl, 100 mM NaCl, 5 mM KCl, 5 mM MgCl2, 0.6%
bovine serum albumin, and 0.5 mg/ml bacitracin, pH 7.4) containing
[125I]Sar1-Ile8-AngII and appropriate levels of unlabeled AngII (0–200
ng/ml) to determine specific and nonspecific binding. After 90 min of
incubation, free ligand was removed by washing three times in ice-cold
binding buffer. The cells were then solubilized with 0.3 M NaOH and
counted on a  counter. HEK cell surface receptor expression was
examined by the receptor binding assay described above, except the
radiolabel used was [3H]AngII (40 nM). Kidneys from three caveolin-1
null mice and three age-matched wild type black-6 control mice were
excised, and radioreceptor assays were performed as previously de-
scribed (43). AT1-R affinity constant and expression levels were deter-
mined using Graphpad Prism (Graphpad Software Inc.). Total protein
was determined by the Bradford reaction described and was used to
standardize AT1-R expression levels.
Immunoprecipitation—Transfected BHK cells were washed in ice-
cold phosphate-buffered saline and scraped into 0.3 ml of Buffer B (50
mM Tris-HCl, pH 7.5, 150 mM NaCl, 4 mg/ml n-dodecyl -maltoside, 0.5
mg/ml cholesteryl hemisuccinate, 1 mM phenylmethylsulfonyl fluoride,
5 g/ml leupeptin, 1 g/ml aprotonin, and 1 g/ml pepstatin). After 1 h
of incubation, the cells were harvested by centrifugation (14,000  g for
15 min). The protein content was determined by the Bradford reaction,
and 1 mg of lysate was used for immunoprecipitation. After preclearing
for 2 h with agarose beads, the lysates were incubated overnight with 20
l of protein G-agarose and mouse anti-HA antisera (1:150) or 20 l of
protein A-agarose and rabbit anti-GFP antisera (1:150). The immuno-
precipitates were washed twice with ice-cold washing buffer 1 (50 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxy-
cholate, 1 mM phenylmethylsulfonyl fluoride, 5 g/ml leupeptin, 1 g/ml
aprotonin, and 1 g/ml pepstatin), twice with washing buffer 2 (50 mM
Tris-HCl, pH 7.5, 500 mM NaCl, 0.1% Triton X-100, 0.05% sodium
deoxycholate), and once with washing buffer 3 (50 mM Tris-HCl, pH 7.5,
0.1% Triton X-100, 0.05% sodium deoxycholate). The proteins were
eluted in 55 l of SDS-PAGE sample buffer.
RESULTS
Activated AT1-R Localizes to Lipid Rafts but Not Caveolae—
Sucrose gradient fractionation experiments have shown that
stimulation with AngII causes AT1-R to shift from dense to
light membranes that co-fractionate with caveolin (27). These
data indicate that activated AT1-R associates with lipid rafts or
caveolae or both, because these microdomains have similar
biophysical properties. To discriminate between these possibil-
ities, we examined the surface distribution of AT1-R in intact
plasma membrane using electron microscopy. BHK cells ex-
pressing GFP-tagged AT1-R were stimulated with AngII or left
untreated, and apical plasma membrane sheets were ripped off
directly onto electron microscopy grids. The sheets were fixed
and stained with affinity-purified anti-GFP antisera coupled
directly to 5-nm gold. In parallel experiments the cells were
also treated with methyl -cyclodextrin for 30 min to disrupt
cholesterol-rich lipid rafts and caveolae. Caveolae are readily
identifiable by their morphology, size, and labeling for caveolin.
No significant labeling of caveolae for AT1-R was evident in
AngII-treated or control cells, although gold labeling was
readily apparent in other areas of the plasma membrane (Fig.
1C). Inspection of the noncaveolar AT1-R gold distribution sug-
gested that it was clustered (Fig. 1A); we therefore analyzed
the gold patterns further using spatial statistics. K-function
analysis reveals that the AT1-R is not randomly distributed
over the cell surface but is localized to clusters with a mean
radius of 20–30 nm (Fig. 1D). Cyclodextrin treatment de-
creased but did not cause a complete loss of clustering (Fig. 1,
B and D). Stimulation with AngII for 10 min caused a signifi-
cant increase in AT1-R clustering, an effect that was blocked in
the presence of cyclodextrin (Fig. 1E). These results indicate
that unstimulated AT1-R is resident in lipid rafts and in cho-
lesterol-independent, nonlipid raft microdomains but that ac-
tivation is accompanied by a shift of AT1-R into cyclodextrin-
sensitive lipid rafts. The extent of this movement can be
estimated by mathematical modeling (Fig. 1F); the observed
change in AT1-R clustering would be achieved if 40% of the
AT1-R in nonraft clusters moved into lipid rafts with AngII
stimulation.
Formation of Caveolin 3AT1-R Complexes Is Dependent on
an Intact CSD—Previous work has shown that AT1-R co-im-
munoprecipitates with Cav1 from vascular smooth muscle cell
lysates (27). Fig. 2 shows identical results for AT1-R and Cav3
FIG. 1. Microlocalization of GFP-AT1-R on immunogold la-
beled plasma membrane sheets. Plasma membrane sheets prepared
from BHK cells expressing GFP-AT1-R were immunogold-labeled with
-GFP-5 nm. No visual differences are apparent in the labeling for
GFP-AT1-R between basal serum-starved (A) and AngII-stimulated
cells (B). Caveolae (arrowheads) are typically devoid of GFP-AT1-R
label (C). Bars, 100 nm; arrowhead, caveolae. Pooled K-function anal-
yses of the spatial distributions of GFP-AT1-R in basal cells (D) or
AngII-stimulated cells (E) in the absence (closed squares) or presence
(open squares) of 1% methyl -cyclodextrin are shown. L(r)-r values
above the 99% confidence interval for complete spatial randomness
(closed circles) indicate clustering at that value of r. GFP-AT1-R shows
maximal deflections from complete spatial randomness at r  20–30
nm for all conditions. GFP-AT1-R clustering increases upon activation
(D and E, closed squares). Although both inactive and stimulated GFP-
AT1-R shows some cholesterol-independent clustering, all of the in-
creased clustering of GFP-AT1-R induced by AngII activation is choles-
terol-dependent (i.e. abolished by cyclodextrin treatment). K-functions
are the means (n  9 areas quantified, 500–1000 gold particles for each
condition) standardized on the 99% confidence interval. F, a mathemat-
ical model was used to derive an estimate of the fraction of AT1-R
migrating into lipid rafts (“Experimental Procedures”). The results
shown in D and E indicate that GFP-AT1-R occupies both lipid rafts and
cholesterol-independent nonraft microdomains. Multiple (385) models
of AT1-R distributed across lipid rafts and cholesterol-independent non-
raft microdomains on a background of randomly distributed receptor
were therefore evaluated. The relative distributions of AT1-R that best
fit the L(r)-r curves in D and E (closed squares) are shown (these models
returned root mean square deviation values of 0.0529 and 0.0507,
respectively).
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ectopically expressed in BHK cells. However, because Fig. 1
shows that the AT1-R is not localized to surface caveolae in
these cells, we investigated where else in the cell the AT1-
Rcaveolin complex may form. The AT1-R protein contains a
consensus site for interaction with the CSD; the sequence,
Tyr302–Tyr312, is located at the C-terminal extremity of the last
transmembrane domain of the receptor and the proximal por-
tion of the C terminus (Fig. 2A). We first examined whether an
intact CSD was required to form the Cav3AT1-R complex using
a series of previously characterized Cav3 mutants (Fig. 2B).
CavDGV and CavLLS are N-terminal truncations at amino
acids 55 and 75, respectively, such that CavDGV but not Cav-
LLS retains the CSD. CavDGV-G55S contains a point mutation
within the retained CSD. Cav3-P104L contains a naturally
occurring point mutation that has been associated with mild
forms of limb girdle muscular dystrophy (44). The P104L point
mutation does not affect the CSD but rather prevents normal
trafficking of caveolin leading to Golgi accumulation (45). Cell
lysates from cells co-expressing each HA-tagged Cav3 mutant
and GFP-tagged AT1-R were normalized for AT1-R content,
immunoprecipitated with anti-GFP antiserum, and immuno-
blotted with anti-HA antisera. Fig. 2C shows that wild type
Cav3, CavDGV, and Cav3-P104L all co-immunoprecipitate
with the AT1-R. However, deletion of the CSD totally abolishes
the ability of CavLLS, and mutation of the CSD significantly
reduces the ability of CavDGV-G55S to form stable complexes
with the AT1-R (Fig. 2, C and D). These observations show that
the AT1-R and Cav3 form a stable complex and that the CSD is
critically important for Cav3/AT1-R interaction.
Mislocalized Cav3 Mutants Sequester the AT1-R as It Traffics
to the Plasma Membrane—The preceding results suggest that
the caveolinAT1-R complex may have a biological role other
than coordinating signaling at the plasma membrane. Caveolin
has recently been shown to be involved in glycosylphosphati-
dylinositol-linked protein trafficking to the plasma membrane
(46), although no such data are available for seven transmem-
brane-spanning receptors. To investigate whether Cav3 was
important in AT1-R trafficking, we examined the subcellular
localization of the AT1-R in cells expressing mislocalized Cav3
mutants. In BHK cells transfected with HA-tagged AT1-R,
either alone or with wild type Cav3, the receptor was exten-
sively localized to the plasma membrane with a small Golgi
pool (Fig. 3A). Co-expression with CavDGV caused a striking
loss of plasma membrane staining for the AT1-R, which now
localized extensively to areas containing lipid bodies marked by
CavDGV. Lipid bodies are derived from the endoplasmic retic-
ulum (11). CavLLS also accumulates in lipid bodies, but AT1-R
localized normally to the plasma membrane in CavLLS-ex-
pressing cells. Expression of Golgi-localized Cav3-P104L, how-
ever, reduced plasma membrane staining for the AT1-R and
substantially increased the Golgi pool of the receptor (Fig. 3A).
To verify that AT1-R mislocalization is not due to a general
disruption of the exocytic pathway or ER architecture induced
by the expression of mutant caveolins, we co-expressed GFP-tH
(GFP appended with the minimal plasma membrane targeting
sequences of H-Ras) or GFP-Icmt (isoprenyl carboxyl methyl-
transferase) with CavDGV and Cav3P104L (Fig. 3B). Neither
the subcellular localization of GFP-tH, a palmitoylated, prenyl-
ated peripheral membrane protein that traffics through the
exocytic pathway to the plasma membrane (37), nor GFP-Icmt,
a tetraspan integral ER membrane protein (47), was affected
by CavDGV or Cav3-P104L expression.
The AT1-R undergoes endocytic recycling after activation at
the plasma membrane (48). We reasoned that very little AT1-R
endocytosis was likely to occur in the absence of AngII stimu-
lation, but to confirm that the effects of the Cav3 mutants were
due to perturbations of forward traffic through the exocytic
pathway, we examined the subcellular localization of an AT1-R
that is poorly internalized because of a truncation at Lys325
(33). The truncated receptor, AT1-R,TK325, is expressed at a
level similar to that of the wild type receptor. The AT1-R,TK325
localized predominately to the plasma membrane of BHK cells
when expressed alone or with wild type Cav3 or CavLLS.
However, as with the full-length AT1-R, co-expression with
CavDGV or Cav3-P104L sequestered AT1-TK325 to lipid bodies
or the Golgi, respectively, with a concomitant loss of plasma
FIG. 2. Formation of an AT1-RCav3 complex requires an intact
caveolin scaffolding domain. A, the AT1-R protein sequence reveals
a consensus binding site (highlighted) for the CSD between Tyr302 and
Tyr312 (302YXFXXXXFXXY312) comprising the C-terminal extremity of
the last transmembrane domain of the receptor and the proximal C
terminus (helix VIII). B, to determine whether the caveolin scaffolding
domain (highlighted) is important in the formation of the Cav3AT1-R
complex, the Cav3 mutants shown were used. C, BHK cells were trans-
fected with GFP-AT1-R (that contains both a N-terminal HA tag and a
C-terminal GFP tag) alone or in combination with HA-tagged Cav3,
Cav3-P104L, CavDGV, and CavDGV-G55S. An anti-GFP (polyclonal)
antibody was used to immunoprecipitate (IP) GFP-AT1-R. Because the
receptor is also HA-tagged, AT1-R (top panel) and Cav3 or Cav3 mu-
tants (middle panel) are visualized by an anti-HA immunoblot. To
ensure that the Cav3 constructs were expressed at detectable levels
prior to immunoprecipitation, Western blot (WB) analysis of whole cell
lysates using an anti-HA antibody was performed (bottom panel). D,
BHK cells were transfected with GFP-AT1-R in combination with empty
GFP vector, GFP-CavDGV or GFP-CavLLS. AT1-R was immunoprecipi-
tated from cell lysates using a monoclonal anti-HA antibody. Because
the AT1-R, CavDGV, and CavLLS are all GFP-labeled, immunoblotting
with a polyclonal anti-GFP antibody visualizes all of the transfected
proteins present in the immunoprecipitate. Equal amounts of AT1-R
were present in all immunoprecipitates (top panel), whereas CavDGV
but not CavLLS co-immunoprecipitated with the AT1-R (middle panel).
To ensure that the inability of CavLLS to immunoprecipitate with the
AT1-R was not due to a lack of CavLLS expression, Western blots of
whole cell lysates were performed using an anti-GFP antibody (bottom
panel). To determine the fraction of total Cav3 that was bound to the
AT1-R, densitometry was performed on the Cav3 immunoblots in the
middle and lower panels of C. We estimate that 2% of the total Cav3
in the cell lysate was complexed with the AT1-R; this is consistent with
an interaction restricted to trafficking through the exocytic pathway.
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membrane staining (Fig. 4). We conclude that the AT1-R and
caveolin interact at multiple stages during the exocytic path-
way between the ER and the Golgi, even though there is no
substantial co-localization of these proteins at the plasma
membrane.
Cav3 Mutants Decrease the Expression of the AT1-R on the
Cell Surface in a Cholesterol-independent Manner—To accu-
rately quantify the effects of impaired trafficking through the
exocytic pathway, we examined changes in AT1-R protein levels
and cell surface expression by Western analysis and radiore-
ceptor assays. Immunoblotting showed that the AT1-R is ex-
pressed in BHK cells as a single band 38 kDa in size repre-
senting the unglycosylated immature receptor and a smear
portion ranging from 60 to 116 kDa in size representing the
glycosylated or mature receptor (Fig. 5A). Co-expression with
wild type Cav3 had no effect on AT1-R expression or matura-
tion (Fig. 5A). Co-expression of Cav3-P104L or CavDGV re-
sulted in a significant decrease in AT1-R expression and mat-
uration. In contrast, CavLLS and CavDGV-G55S expression
had no effect on AT1-R expression level or maturation (Fig. 5A).
Identical effects were seen for the noninternalizing AT1-
R,TK325 (data not shown).
To verify that changes in AT1-R protein levels reflected cell
surface expression, we performed radioreceptor assays. BHK
cells transfected with the AT1-R showed a relatively high level
of receptor expression (960  60 fmol/mg protein) as measured
by competition binding studies using [125I]Sar1-Ile8-AngII.
These assays also revealed that the tagged receptor had a high
affinity for [125I]Sar1-Ile8-AngII (Kd  2.1 nM). AT1-R ligand
binding was down-regulated by co-expression of CavDGV and
Cav3-P104L but was unaffected by wild type Cav3, CavDGV-
G55S, or CavLLS (Fig. 5B). Scatchard analysis indicated that
the decrease in radioligand binding was due to a decrease in
receptor numbers at the cell surface and not due to a change in
receptor affinity (data not shown). These results show that
expression of mislocalized Cav3 mutants with an intact CSD
prevent AT1-R expression at the cell surface, consistent with a
major role for caveolin in maintaining normal plasma mem-
brane levels of the AT1-R.
Expression of CavDGV has been shown previously to have a
major effect on cholesterol distribution, resulting in a decrease
in plasma membrane cholesterol and an increase in intracellu-
lar compartments (11, 49). The CavDGV-induced decrease in
plasma membrane cholesterol interferes with lipid raft-
dependent signaling and can be reversed by supplementing
cells with exogenous cholesterol (49). We therefore investigated
whether the effects of CavDGV on AT1-R trafficking were a
result of changes in cellular cholesterol. Fig. 6A shows that this
is not the case. The reduction of AT1-R levels in cells expressing
FIG. 3. Cav3 specifically interacts with the AT1-R in the Golgi
and endoplasmic reticulum. A, BHK cells were transfected with
HA-tagged AT1-R alone or in combination with mislocalized GFP-
CavDGV, GFP-CavLLS, and GFP-Cav3-P104L. B, as controls BHK
cells were transfected with GFP-tH alone or in combination with HA-
tagged CavDGV and Cav3-P104L, or with GFP-Icmt and HA-tagged
CavDGV (lower panel). GFP was visualized by direct, and HA-tagged
proteins were visualized by indirect immunofluorescence. Mislocaliza-
tion of Cav3 to lipid bodies (CavDGV) or the Golgi (Cav3-P104L) se-
questers AT1-R but not GFP-tH or GFP-Icmt to these structures. Al-
though CavLLS localizes to lipid bodies, co-expression has no effect on
AT1-R localization.
FIG. 4. Cav3 interacts with AT1-R in the exocytic pathway.
BHK cells were transfected with HA-tagged, truncated AT1-R (AT1-
R,TK325) alone or in combination with mislocalized GFP-CavDGV,
GFP-CavLLS, and GFP-Cav3-P104L. Mislocalization of Cav3 to lipid
bodies (CavDGV) or the Golgi (Cav3-P104L) sequesters the AT1-
R,TK325 to these structures. Although CavLLS localizes to lipid bodies,
co-expression has no effect on AT1-R,TK325 localization.
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CavDGV was not alleviated by the addition of cholesterol.
Furthermore mimicking the effect of CavDGV on cell surface
cholesterol by treating cells with methyl -cyclodextrin had no
effect on the expression or maturation of the AT1-R (Fig. 6B).
We conclude that the effect of CavDGV in sequestering the
AT1-R to lipid bodies is due to the formation of a
CavDGVAT1-R complex rather than an indirect effect on cho-
lesterol distribution.
Mutation of the AT1-R Putative Caveolin-binding Site De-
creases AT1-R Expression—We have shown that caveolin is
important for the transport of AT1-R to the plasma membrane
and that the CSD is required for AT1-R binding. Within the
putative CSD-binding domain at the proximal end of the C-
terminal tail of the AT1-R is a group of positively charged
residues that may be responsible for tethering the carboxyl tail
of the AT1-R in a conformation that allows G-protein interac-
tion (49) and four aromatic residues that comprise the recog-
nition sequence for CSD binding (21–23). To investigate the
relative contribution of these sets of residues to AT1-R traffick-
ing, they were separately mutated; the four aromatic residues
were replaced with alanine (AT1-R,YFFY/A), and the charge on
the four lysines was neutralized by mutation to glutamine
(AT1-R, KKKK/Q). When transfected into HEK cells, Western
analysis and radioreceptor assays showed that mature AT1-
R,KKKK/Q but not AT1-R,YFFY/A was expressed at the cell
surface (Fig. 7). These results indicate that the CSD-binding
site of AT1-R but not the overlapping polybasic domain is
required for trafficking to the plasma membrane. In addition,
the observation that loss of the CSD-binding site affects the
mature and not the immature form of the AT1-R is consistent
with the hypothesis that caveolin is required for the matura-
tion of the receptor.
Caveolin Is Required for AT1-R Surface Expression in FRT
Cells and Mouse Kidney—All of the experiments described
above were conducted in cells that express endogenous caveo-
lin. We therefore next wanted to examine AT1-R transport to
the cell surface in cells that lack caveolin. To this end we first
expressed AT1-R in FRT cells that do not express Cav1 or Cav3
(51). Fig. 8A shows that AT1-R expression in FRT cells is
limited to the ER; strikingly, however, co-expression of Cav3 or
Cav1 redistributes the AT1-R from the ER to the plasma mem-
brane. To verify the physiological significance of these obser-
vations, we investigated endogenous AT1-R expression in Cav1
null mice using radioreceptor assays. We measured AT1-R lev-
els in the kidney, because they have been shown to normally
co-express Cav1 (43, 52). Scatchard analysis showed that Cav1
null mice express 55% less renal AT1-R than age-matched wild
type control mice, with no change in receptor affinity (Fig. 8B).
These data therefore indicate that wild type caveolin is re-
quired for efficient surface expression of AT1-R in tissue culture
cells and in an intact animal.
DISCUSSION
In this study we investigated the role of caveolin in AT1-R
localization and trafficking. Electron microscopy of intact
plasma membrane sheets immunogold-labeled for caveolin and
AT1-R clearly shows that the receptor is not concentrated in
caveolae. However, more detailed analysis of the AT1-R immu-
nogold patterns that decorate morphologically featureless ar-
FIG. 5. AT1-R expression at the plasma membrane is decreased
in the presence of CavDGV and Cav3-P104L. A, BHK cells were
transfected with HA-tagged AT1-R alone or in combination with Cav3,
CavDGV, CavLLS, CavDGV-G55S, and Cav3-P104L. P100 membrane
fractions were Western blotted (WB) for AT1-R using an anti-HA anti-
body. The AT1-R has a lower unglycosylated (immature; molecular
mass, 38–40 kDa) and a glycosylated (mature; molecular mass, 65–110
kDa) form. CavDGV and Cav3-P104L cause a significant decrease in
AT1-R expression, whereas Cav3, CavDGV-G55S, and CavLLS do not.
B, radioreceptor assays were performed on BHK cells transfected with
AT1-R alone or in combination with Cav3 wild type or Cav3 mutants as
indicated. A significant reduction of AT1-R at the cell surface was
observed in cells that co-express CavDGV or Cav3-P104L.
FIG. 6. CavDGV-induced decrease in AT1-R expression is cho-
lesterol independent. BHK cells transfected with AT1-R alone or in
combination with CavDGV were treated as indicated. Cell lysates were
separated into P100 (P) and S100 (S) fractions, and AT1-R was detected
by Western blot using an anti-HA antibody. A, BHK cells co-expressing
the AT1-R and CavDGV were repleted with cholesterol for 1 h by
incubation in DMEM supplemented with 16 g/ml cholesterol in 0.4%
cyclodextrin (39). B, BHK cells expressing the AT1-R alone were de-
pleted of cell surface cholesterol by incubation for 30 min in DMEM
containing 1% cyclodextrin. The replenishment of cholesterol had no
effect on the CavDGV-induced decrease in AT1-R expression. Similarly
cholesterol depletion had no effect on the level of AT1-R protein
expressed.
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eas of the plasma membrane reveals that the inactive AT1-R is
clustered in both cyclodextrin-resistant and cyclodextrin-sensi-
tive microdomains. The cyclodextrin-sensitive pool is most
probably AT1-R associated with lipid rafts. The nature of the
nonlipid raft microdomain is yet to be determined. Activation of
the AT1-R results in an increased degree of clustering that is
completely sensitive to cyclodextrin treatment. The simplest
interpretation of these results is that activation of the AT1-R is
accompanied by a migration of the receptor into lipid rafts. As
with the AT1-R, early work suggested that the EGF receptor
might be localized to caveolae (25), although recent electron
microscopy studies have shown that the EGF-R is actually
localized to noncaveolar lipid rafts (32). The EGF-R is transac-
tivated by the AT1-R and mediates many AngII growth promot-
ing effects, suggesting that the receptors must be at some stage
in close proximity to each other. In light of the data presented
here, we suggest that transactivation of the EGF receptor by
the AT1-R occurs in noncaveolar lipid rafts and not caveolae as
previously proposed (31).
Although electron microscopy studies suggest that caveolin
does not directly interact with the AT1-R at the cell surface,
several lines of evidence show that caveolin plays a central role
in trafficking the AT1-R to the plasma membrane. CavDGV
sequesters the AT1-R to lipid bodies, structures derived from
the ER, leading to a decreased level of mature and immature
receptor. Core glycosylation and N-glycosylation occur in the
ER and Golgi, respectively; CavDGV must therefore bind to
newly synthesized AT1-R and prevent it traveling through the
ER and Golgi. The CavDGV compartment is accessible to wild
type caveolin (11), so we suggest that the AT1-RCav3 complex
is formed during the initial stage of AT1-R maturation in the
ER. We speculate that the AT1-RCav3 complex remains intact
at least until it reaches the Golgi because Golgi-localized Cav3-
P104L also impairs AT1-R forward trafficking, resulting in a
significant decrease in protein and plasma membrane levels.
The AT1-R complex must then be dismantled somewhere be-
tween the Golgi and the plasma membrane or after arriving at
the plasma membrane. Moreover, as expected from an interac-
tion restricted to the exocytic pathway, only a small fraction
(2%) of caveolin can be recovered from the cell lysates bound to
AT1-R. The association of the AT1-R with lipid bodies seen by
FIG. 7. Selective mutation of the AT1-R putative CSD binding
motif reduces AT1-R at the plasma membrane. A, HEK cells were
transfected with vector alone (lane 1), AT1-R (lane 2), AT1-R, KKK/Q
(lane 3), or AT1-R, YFFY/A (lane 4). Whole cell lysates were Western
blotted for AT1-R using an anti-HA antibody. In HEK cells, as in BHK
cells, AT1-R is expressed in an immature (lower bands) and mature (top
smear) form. Mutation of the positively charged lysine residues (AT1-
R,KKKK/Q) in the CSD binding motif did not significantly alter the
level of protein expressed. In contrast mutation of the aromatic residues
(AT1-R,YFFY/A) within the AT1-R CSD-binding motif resulted in a
dramatic decrease in the level of the mature but not the immature form
of the AT1-R. B, radioreceptor assays were performed on transfected
HEK cells as indicated. A significant reduction of AT1-R at the cell
surface was observed in cells that expressed the AT1-R,YFFY/A form of
the AT1-R.
FIG. 8. Absence of caveolin reduces AT1-R expression in vivo
and in vitro. A, FRT cells were electroporated with GFP-AT1-R alone
or in combination with HA-tagged Cav3 or Cav1. GFP was visualized by
direct immunofluorescence. Cav1 and Cav3 expression was detected by
indirect immunofluorescence using an anti-Cav1, anti-Cav3 antibody.
In the absence of ectopically expressed Cav3 or Cav1 in FRT cells (no
caveolin staining), AT1-R is exclusively expressed in the ER. Expression
of Cav3 or Cav1 causes a redistribution of the AT1-R from the ER to the
plasma membrane. B, the kidneys of Cav1 null and wild type mice were
excised, and a radioreceptor assay was performed to determine the
relative level of AT1-R expressed. Scatchard analysis indicated that
wild type mice express more than twice the amount of AT1-R than Cav1
null mice. The data shown are the means  S.E. (n  3). No change in
receptor affinity (data not shown) between the two groups was
observed.
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light microscopy is itself interesting. The lipid body core is
surrounded by a single phospholipid monolayer that cannot
accommodate transmembrane proteins (53). We therefore en-
visage that the association of AT1-R with CavDGV-induced
lipid bodies might involve an enwrapping membrane system, a
common feature of lipid bodies in mammalian cells (11, 53, 54).
In this model, caveolin present on the cytosolic side of the lipid
body would interact with the C terminus of the AT1-R on the
membrane bilayer surrounding the lipid body.
A role for caveolin in AT1-R transport to the cell surface is
also strongly supported by the observation that in FRT cells
lacking Cav1 and Cav3; AT1-R remains in the ER unless Cav1
or Cav3 are ectopically expressed. Similarly, mutation of the
aromatic residues in the AT1-R caveolin-binding motif that are
known to be important for caveolin binding confines the AT1-R
to the ER and selectively reduces levels of mature but not
immature receptor. Finally, we have observed that endogenous
renal AT1-R levels are substantially lower in Cav1 null mice
compared with wild type controls. Caveolin has recently been
identified as a trafficking chaperone for glycosylphosphatidyl-
inositol-anchored proteins. In fibroblasts derived from Cav1
null mice, glycosylphosphatidylinositol-anchored proteins mis-
localize to the Golgi, whereas ectopic expression of Cav1 or
Cav3 restores plasma membrane localization (46). In the pres-
ent study we have now shown that Cav1 and Cav3 also act as
trafficking chaperones for a seven transmembrane-spanning
GPCR. In this context, it is worth noting that Cav1 and Cav3
knockout mice suffer from a variety of cardiovascular patholo-
gies (38, 55, 56). Given that the AT1-R has a major role in
maintaining cardiovascular homeostasis, it is tempting to spec-
ulate that alterations in AT1-R levels, and perhaps those of
other GPCRs (see below), may contribute to some of the car-
diovascular changes observed in mice lacking caveolin. Inter-
estingly Drab et al. (38) observed that AngII-induced vascular
contractility was reduced by 50% in Cav1 null mice. In view
of the results presented here, it seems likely that decreased
AT1-R levels in the vascular smooth muscle cells of Cav1 null
mice contribute to this phenotype.
Does caveolin serve any other function as it traffics through
the exocytic pathway in a complex with the AT1-R? An inter-
esting possibility is that caveolin chaperoning may prevent any
interaction with other signaling proteins during maturation
and transport of the AT1-R. Some GPCR such as the -adre-
nergic receptors are palmitoylated at the C terminus. Palmitic
acid tethering of GPCR C-terminal to the inner leaf of the
plasma membrane is important for G-protein coupling (57). A
similar positioning of the nonpalmitoylated AT1-R C terminus,
however, is dependent on helix VIII and a series of charged
lysine residues at positions 307–311 in this helix (50). The
putative binding site for caveolin overlaps with helix VIII.
Therefore, formation of the AT1-RCav3 complex would cer-
tainly mask and possibly prevent correct C-terminal mem-
brane tethering and perhaps G-protein coupling. When the
caveolinAT1-R complex is dismantled in the Golgi or plasma
membrane, the charged lysine residues would be freed, allow-
ing formation of helix VIII and correct tethering of the C-
terminal receptor tails to the plasma membrane. Interestingly,
sequence analysis of other seven-transmembrane GPCRs re-
veals a subset that like the AT1-R have a polylysine sequence
with an overlapping putative binding sequence for the caveolin
CSD immediately distal to the last transmembrane domain.
These include the human somatostatin receptor type 2A, inter-
leukin receptor type 8a, and neuropeptide Y receptor type 1. It
is possible that this subset of GPCRs traffic to the plasma
membrane using a mechanism similar to that of the AT1-R.
Hypercholesterolemia is a major risk factor for cardiovascu-
lar disease. A relationship between LDL cholesterol levels and
the AT1-R has been shown by numerous studies (58–64). LDL
cholesterol increases AT1-R cell surface expression and signal-
ing in vascular smooth muscle in vitro (59, 60) and in vivo (61).
Clinical studies have also shown that hypercholesterolemic
patients have an increased number of platelet AT1-Rs and
increased responsiveness to AngII infusion compared with nor-
mocholesterolemic patients (62, 63). Furthermore, HMG-CoA
reductase inhibitors, which lower cholesterol, down-regulate
vascular AT1 receptors (64). These studies indicate that cho-
lesterol regulates AT1-R expression. Our study now shows that
caveolin is necessary for correct transport of the AT1-R to the
plasma membrane. Caveolin is also up-regulated by LDL cho-
lesterol and down-regulated by HMG-CoA reductase inhibitors
(30, 65). In light of the data presented here, it is possible that
the effects of cholesterol may in part reflect caveolin-mediated
transport of the AT1-R to the cell surface. Interestingly, caveo-
lin is also involved in the post-translational regulation of en-
dothelial nitric-oxide synthase activity. Lowering LDL choles-
terol reduces caveolin levels and increases endothelial nitric-
oxide synthase signaling (30). Signaling from the AT1-R and
NO are antagonistic in many of their biological functions; thus
caveolin may play a role in maintaining the balance of these
signaling molecules in the cardiovascular system.
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